Notice on Convening the 2025 Annual General Meeting
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference: View Attachment
Notice on Convening the 2025 Annual General Meeting
Filed with SSE ·
6ix hasn’t read this filing yet.
Hinova Pharmaceuticals, Inc. on 6ix
Earlier from Hinova Pharmaceuticals
- Announcement on Change of Sponsor Representative
- Announcement on Voluntary Disclosure of Completion of Inclusion of All Participants in Phase IIa Clinical Trial of the Drug HP515 for Treating Metabolic-Associated Steatohepatitis (MASH)
- Announcement on Preliminary Earnings Estimate for 2025
- Announcement on the Company's Successful GMP Compliance Inspection and the Amendment of Its Drug Manufacturing License
- Earnings Preannouncement for 2025
Later from Hinova Pharmaceuticals
- Announcement on Resolutions of the 2025 Annual General Meeting
- Announcement on Reply to Inquiry Letter for Information Disclosure Supervision of 2025 Annual Report
- Voluntary Disclosure Announcement on Receipt of Notice of Approval for Initiation of a Phase III Clinical Trial of Deuterated Enzalutamide Soft Capsules for High-risk Biochemical Recurrence (BCR) Prostate Cancer
- Announcement on Resolutions of the 18th Meeting of the 2nd Board of Directors
- Announcement on Public Solicitation of Voting Rights by CHINA SECURITIES INVESTOR SERVICES CENTER CO., LTD.
Follow Hinova Pharmaceuticals into a list and get an email when it puts out news.
Follow Hinova Pharmaceuticals